Netherlands' Redcare Pharmacy preliminary Q1 revenue rises 18%

Redcare Pharmacy NV

08/04/2026 06:09

Overview

Netherlands e-pharmacy's preliminary Q1 group revenue rose 18% yr/yr to EUR 848 mln

Non-Rx revenue in Germany rebounded, up 10% yr/yr after slower Q4 growth

Company confirms guidance for 2026

Outlook

Redcare Pharmacy confirms its guidance for 2026

Company expects continued Rx momentum in Germany and Switzerland

Result Drivers

NON-RX REBOUND - Non-Rx revenue growth in Germany accelerated to 10% yr/yr, up from slower growth of 5% in Q4 due to lower marketing spend

RX MOMENTUM - Rx revenue in Germany rose 55% yr/yr, with continued strong growth in Switzerland

CUSTOMER BASE GROWTH - Active customers increased by 1.1 mln yr/yr to 14.2 mln, supporting higher group revenue

Company press release: ID:nEQ1GH2fPa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
EUR 848 mln
EUR 815 mln (1 Analyst)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the drug retailers peer group is "buy"

Wall Street's median 12-month price target for Redcare Pharmacy NV is €95.00, about 166% above its April 7 closing price of €35.72

The stock recently traded at 279 times the next 12-month earnings vs. a P/E of 133 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)